Metastatic adenocarcinoma of unknown primary site: Analysis of 245 patients seen at the johns hopkins hospital from 1965-1979
- 1 January 1982
- journal article
- research article
- Published by Wiley in Medical and Pediatric Oncology
- Vol. 10 (6), 569-574
- https://doi.org/10.1002/mpo.2950100607
Abstract
A retrospective review of 245 patients with metastatic adenocarcinomas of unknown primary site (ACUP) seen at The Johns Hopkins Hospital from 1965‐1979 was undertaken. The median survival was 3.1 months. Age, sex, race, and year of diagnosis did not appear to influence survival. Patients having their major site(s) of disease above the diaphragm experienced a significantly longer survival than patients whose disease was below the diaphragm (5.3 versus 2.3 months, P < 0.05). As a group, patients treated with chemotherapy had no improvement in survival. However, the small number of patients treated with either cyclophosphamide or doxorubicin or both drugs had a median survival of greater than 9 months compared to 2.6 months for untreated or local radiotherapy‐treated patients and 3.2 months for patients treated with 5‐fluorouracil.Keywords
This publication has 7 references indexed in Scilit:
- 5-Fluorouracil, Doxorubicin, and Mitomycin (FAM) Combination Chemotherapy for Advanced Gastric CancerAnnals of Internal Medicine, 1980
- Metastatic Adenocarcinomas of Unknown Primary SiteNew England Journal of Medicine, 1980
- Unknown primary adenocarcinoma: incidence of overinvestigation and natural history.BMJ, 1979
- Adenocarcinoma of unknown primary site: A clinico-pathological studyMedical and Pediatric Oncology, 1979
- Metastatic Carcinomas from Occult Primary TumorsAnnals of Surgery, 1977
- A Handbook of Numerical and Statistical TechniquesPublished by Cambridge University Press (CUP) ,1977
- Treatment of the patient with adenocarcinoma of unknown originCancer, 1972